TNFSF10 and laryngotracheoesophageal cleft: In clinical trials, TRAIL has shown to be effective only in a very small subset of LC patients (76), but, unfortunately, the majority of lung tumors are TRAIL resistant and the causes of this resistance are mostly unknown.